Vela, a trading and market access technology firm, has partnered CoinRoutes, a provider of consolidated data, smart order routing (SOR) and algorithmic trading for crypto investors, in order to extend its crypto-asset SOR offering and achieve optimal aggregate prices across selected crypto exchanges. Peggy Sullivan, chief of staff at Vela, says, “Our partnership with CoinRoutes allows traders to leverage sophisticated SOR and algorithmic strategies to achieve best execution.”
A-Team Insight Blogs
Related content
WEBINAR
Recorded Webinar: MiFID II: Data for transaction reporting
Don’t miss this opportunity to view the recording of this recently held webinar. Markets in Financial Instruments Directive II (MiFID II) is complemented by Markets in Financial Instruments Regulation (MiFIR), which builds out transaction reporting requirements with a number of new reporting obligations. The data and data management challenges of reporting include an increase in...
BLOG
SIFMA 2011 – Booth 1101 – What to Expect
Today is the first day of the annual SIFMA show. And each year since it’s been run at the Hilton, Booth 1101 is the very first one that punters encounter following registration. So in some respects, it sets the tone for the entire trade show, and perhaps what is hot in the financial technology marketplace....
EVENT
TradingTech Summit New York City
Our TradingTech Summit in New York City is aimed at senior-level decision makers in trading technology, electronic execution, trading architecture and offers a day packed with insight from practitioners and from innovative suppliers happy to share their experiences in dealing with the enterprise challenges facing our marketplace.
GUIDE
Alternative Trading Systems Directory 2010
The year since we launched our first edition of the A-Team Alternative Trading Directory has passed by in a flash (no pun intended). And while the rate of expansion of the alternative trading system sector may have slowed – even consolidated somewhat – in the more established centres, their onward march continues both in terms of credibility, and of uptake...